000272508 001__ 272508
000272508 005__ 20250127091437.0
000272508 0247_ $$2pmid$$apmid:39452005
000272508 0247_ $$2doi$$a10.3390/brainsci14100991
000272508 0247_ $$2pmc$$apmc:PMC11506334
000272508 037__ $$aDZNE-2024-01184
000272508 082__ $$a570
000272508 1001_ $$0P:(DE-2719)2811684$$aYe, Lan$$b0
000272508 245__ $$aAcute Levodopa Challenge in Atypical Parkinsonism: Comprehensive Analysis of Individual Motor Responses
000272508 260__ $$aBasel$$bMDPI AG$$c2024
000272508 3367_ $$2DRIVER$$aarticle
000272508 3367_ $$2DataCite$$aOutput Types/Journal article
000272508 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1729168581_2182
000272508 3367_ $$2BibTeX$$aARTICLE
000272508 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000272508 3367_ $$00$$2EndNote$$aJournal Article
000272508 520__ $$a The acute levodopa challenge is widely used to distinguish Parkinson's disease (PD) from atypical parkinsonian syndromes (APSs) such as multiple system atrophy (MSA) and progressive supranuclear palsy (PSP). In APSs, very few patients present a clinically relevant response to levodopa. The aim of this study was to determine whether patients with atypical parkinsonism benefit from levodopa in any aspect of their multiple motor deficits despite the generally poor response. This retrospective study analyzed individual motor responses to the acute levodopa challenge using the MDS-UPDRS III in 47 PSP, 26 MSA, and 71 PD patients at Hannover Medical School. Despite the generally poor levodopa response in both PSP and MSA patients, bradykinesia and rigidity were the symptoms most notably affected by levodopa in PSP patients, while MSA patients experienced significant improvements in bradykinesia and action tremor. These findings underscore the variability in levodopa response among PSP and MSA patients and highlight the need for personalized treatment approaches in atypical parkinsonism.
000272508 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000272508 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000272508 7001_ $$aSani, Sam Sadeghi$$b1
000272508 7001_ $$aVeith Sanches, Linda$$b2
000272508 7001_ $$00009-0000-4768-0259$$aKrey, Lea Farina Magdalena$$b3
000272508 7001_ $$aWegner, Florian$$b4
000272508 7001_ $$aHöllerhage, Matthias$$b5
000272508 7001_ $$00000-0001-5323-8299$$aSchrader, Christoph$$b6
000272508 7001_ $$0P:(DE-2719)2811373$$aHöglinger, Günter$$b7$$udzne
000272508 7001_ $$00000-0002-3054-9905$$aKlietz, Martin$$b8
000272508 770__ $$aNew Approaches in the Exploration of Parkinson’s Disease
000272508 773__ $$0PERI:(DE-600)2651993-8$$a10.3390/brainsci14100991$$gVol. 14, no. 10, p. 991 -$$n10$$p991$$tBrain Sciences$$v14$$x2076-3425$$y2024
000272508 8564_ $$uhttps://pub.dzne.de/record/272508/files/DZNE-2024-01184.pdf$$yOpenAccess
000272508 8564_ $$uhttps://pub.dzne.de/record/272508/files/DZNE-2024-01184.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000272508 909CO $$ooai:pub.dzne.de:272508$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000272508 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811373$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000272508 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000272508 9141_ $$y2024
000272508 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-26
000272508 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-26
000272508 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000272508 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-26
000272508 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRAIN SCI : 2022$$d2023-08-26
000272508 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T14:57:08Z
000272508 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T14:57:08Z
000272508 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-26
000272508 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-26
000272508 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-26
000272508 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-26
000272508 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000272508 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-26
000272508 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-26
000272508 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-26
000272508 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-26
000272508 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-26
000272508 9201_ $$0I:(DE-2719)1110002$$kAG Höglinger$$lTranslational Neurodegeneration$$x0
000272508 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x1
000272508 980__ $$ajournal
000272508 980__ $$aVDB
000272508 980__ $$aUNRESTRICTED
000272508 980__ $$aI:(DE-2719)1110002
000272508 980__ $$aI:(DE-2719)1111015
000272508 9801_ $$aFullTexts